SATURDAY, OCTOBER 1, 2016

Menon Biosensors successfully detects plague in thousands of samples

Menon Biosensors, a San Diego-based molecular biochemistry company, announced on Thursday that its nuclear magnetic resonance technology successfully detected Yersinia pestis in more than 2,200 samples without any false positives or negatives.

Over a six-year period, Menon Biosensors' platform technology detected the presence of the biological pathogen, which is also known as the plague, in blood, air, water, urine, stool and sputum in concentrations as low as one colony-forming unit per sample. The company is currently conducting validation studies at Scripps La Jolla for Mycobacterium tuberculosis and Clostridium difficile.

"Having reviewed the new diagnostic technology, process and assay data generated using Menon Biosensors' technology in identifying several well-known pathogens, I believe this technology provides a foundation to achieve a more facile, next-generation DNA diagnostic platform," John Spinosa, a pathologist at Scripps La Jolla, said. "Menon Biosensors' technology has significant implications in molecular biochemistry diagnostic applications for improving patient care and outcomes in an affordable and streamlined manner."

In multiple studies with the U.S. government's biodefense program, Menon Biosensors' platform technology demonstrated better than 99 percent accuracy in less than one hour from the time a sample was collected.

"This data demonstrates that our technology can more accurately and rapidly detect a biological pathogen compared to currently available tests, and with higher sensitivity," David Schlotterbeck, the chairman of Menon Biosensors, said. "With our upcoming data in C. difficile and TB, we plan to demonstrate that it can be easily and accurately applied to different pathogens with assays developed in less than six months."